Dcf Advisers, LLC Esperion Therapeutics, Inc. Transaction History

Dcf Advisers, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$19.4 - $28.71 $335,348 - $496,281	-17,286 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$25.12 - $36.89 $532,895 - $782,584	-21,214 Reduced 55.1%	17,286 $485,000
Q4 2020 Feb 12, 2021	SELL	$24.2 - $35.76 $435,600 - $643,680	-18,000 Reduced 31.86%	38,500 $1 Million
Q3 2020 Nov 13, 2020	BUY	$31.18 - $52.71 $249,440 - $421,680	8,000 Added 16.49%	56,500 $2.1 Million
Q2 2020 Aug 13, 2020	BUY	$30.04 - $51.31 $796,060 - $1.36 Million	26,500 Added 120.45%	48,500 $2.49 Million
Q1 2020 May 12, 2020	BUY	$27.44 - $73.84 $192,080 - $516,880	7,000 Added 46.67%	22,000 $694,000
Q4 2019 Feb 12, 2020	BUY	$35.4 - $59.82 $531,000 - $897,300	15,000 New	15,000 $894,000

206

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $153M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Dcf Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Dcf Advisers, LLC with notifications on news.